Lupin receives EIR from USFDA

Lupin receives EIR from USFDA for its Vizag facility

313
Document
Picture: Pixabay

Last Updated on May 15, 2020 by The Health Master

Lupin receives EIR from USFDA

Mumbai: Pharma major Lupin Limited (Lupin) today announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) after closure of the inspection for its Vizag (Vishakhapatnam), India facility.

The inspection for the API facility was conducted by the U.S. FDA between January 13, 2020 and January 17, 2020.

Also read: Dr. Reddy’s receives EIR from USFDA

Vizag facility

Commenting on the receipt of the EIR, Nilesh Gupta, Managing Director, Lupin said, “We are very happy to have received the EIR for our Vizag facility. We remain committed to enhancing compliance and quality standards at the Vizag facility and across all our manufacturing sites.”

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.